ASP Isotopes remains an industry growth leader on a headline basis, but weak quality metrics, a confirmed technical downtrend, heavy insider selling, and repeated earnings misses argue for caution despite deeply oversold conditions.
Thesis pillars
- Quality Below Engine Floor→Stable
- Confirmed Technical Downtrend↑Improving
- Heavy Insider Selling Gate Failed→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Apr 10, 2026· older than 90 days
ASP Isotopes Inc. (ASPI) Stock Analysis
Basic Materials · Specialty Chemicals
Hold if already holding. Not a fresh buy at $1.91, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $13.00 vs price $1.91 — ratio 6.8×). Rejected, falling back to technical TP.; Market cap $293M below $400M minimum.
ASP Isotopes is an advanced materials company developing proprietary Aerodynamic Separation Process and Quantum Enrichment technologies to produce enriched isotopes, including Carbon-14, Silicon-28, and Ytterbium-176, for nuclear medicine, semiconductor, and nuclear energy... Read more
Hold if already holding. Not a fresh buy at $1.91, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $13.00 vs price $1.91 — ratio 6.8×). Rejected, falling back to technical TP.; Market cap $293M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $293M below $400M minimum. Not in investable universe. Score 3.9/10, high confidence.
Passes 4/9 gates (no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: speculative.
About ASP Isotopes Inc.
About ASP Isotopes Inc.
ASP Isotopes operates three enrichment facilities in Pretoria, South Africa, producing Carbon-14, Silicon-28, and Ytterbium-176 for nuclear medicine, semiconductor, and radiotherapeutic applications, targeting initial commercial shipments in mid-2026. The company has generated no revenue from enriched isotopes to date, reported a $159.8 million net loss in 2025 on a $231.3 million accumulated deficit, and in January 2026 acquired Renergen, South Africa's only integrated onshore natural gas, LNG, and liquid helium producer.
ASP Isotopes plans a corporate separation of its Nuclear Fuels business, run through subsidiary Quantum Leap Energy (QLE), from its Specialist Isotopes and Related Services business, having confidentially filed a draft S-1 for a QLE initial public offering in November 2025; QLE licenses ASP's enrichment technology under a perpetual 10%-of-revenue royalty. QLE has entered definitive agreements with TerraPower, including a term loan supporting construction of a uranium enrichment facility at Pelindaba, South Africa, and supply agreements to provide TerraPower with HALEU nuclear fuel, alongside a services contract with state-owned Necsa for facility siting and construction support. On the medical-isotope side, the company holds a 51% stake in PET Labs (with an option on the remaining 49% through January 2027) and acquired East Coast Nuclear Pharmacy in October 2025 to build downstream radiopharmaceutical distribution. Renergen's helium and LNG operations depend on a single South African production right, valid through September 2042, covering the Virginia Gas Project, and Renergen also carries debt under DFC and IDC loan agreements that impose operating restrictions.
Show full overview
ASP Isotopes has not yet generated commercial isotope revenue, but the 10-K already flags that once sales begin, the company expects to be heavily dependent on a few large customers for a majority of revenue, a concentration mirrored in its nuclear-fuels business, where QLE's uranium-enrichment strategy currently rests on definitive agreements with a single named counterparty, TerraPower, for both construction financing and future HALEU offtake. Because QLE has not yet received regulatory approval to test its enrichment technology on U-235 outside a narrow services contract with Necsa, the commercial thesis for the largest piece of ASP's diversification, nuclear fuel, depends on both a single customer relationship maturing and a regulatory approval not yet granted.
See also: Basic Materials · Specialty Chemicals
From ASP Isotopes Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — ASP Isotopes Inc.
Latest news
- NEWS ASP Isotopes Provides Operational Updates on Silicon-28 and Ytterbium-176 Production — fiscal.ai Nov 3, 2026
- NEWS ASP Isotopes Enters Definitive Agreements with TerraPower for HALEU Production — fiscal.ai Oct 29, 2026
- NEWS ASP Isotopes to Present at the 97th Emerging Growth Conference — fiscal.ai Oct 28, 2026
- NEWS ASP Isotopes Inc. Announces Stable Liquid Helium Production at Renergen Limited's Virginia Gas Project — fiscal.ai Oct 26, 2026
- NEWS 12 Materials Stocks Moving In Monday's Pre-Market Session — benzinga Oct 26, 2026
Latest item Nov 3, 2026 · Generated 2026-11-05T12:04:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomera few large customers10-K Item 1A: 'We currently have no sales attributable to enriched isotopes, but we expect to be heavily dependent on a few large customers to generate a majority of our revenues.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $1.91, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $13.00 vs price $1.91 — ratio 6.8×). Rejected, falling back to technical TP.; Market cap $293M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $293M below $400M minimum. Not in investable universe. Resistance target $2.87 (+50.3%), stop $1.78 (−7.3%), A.R:R 0.0:1. Score 3.9/10, high confidence.
Resistance target: $2.87 (+50.3% upside). Resistance target $2.87 (+50.3%), stop $1.78 (−7.3%), A.R:R 0.0:1. Stop-loss: $1.78.
DATA_ISSUE: analyst_target_implausible (raw $13.00 vs price $1.91 — ratio 6.8×). Rejected, falling back to technical TP.; Market cap $293M below $400M minimum.
ASP Isotopes Inc. trades at a P/E of N/A (forward -2.3). TrendMatrix value score: 3.8/10. Verdict: Hold.
9 analysts rate ASPI, with a consensus score of 4.1/5. 3 analysts publish price targets averaging $13.
What does ASP Isotopes Inc. do?ASP Isotopes is an advanced materials company developing proprietary Aerodynamic Separation Process and Quantum...
ASP Isotopes is an advanced materials company developing proprietary Aerodynamic Separation Process and Quantum Enrichment technologies to produce enriched isotopes, including Carbon-14, Silicon-28, and Ytterbium-176, for nuclear medicine, semiconductor, and nuclear energy applications, targeting initial commercial shipments in mid-2026. Through subsidiary Quantum Leap Energy, it is also pursuing HALEU uranium enrichment under agreements with TerraPower, and in January 2026 it acquired Renergen, South Africa's only integrated onshore natural gas, LNG, and liquid helium producer; the company ha